Current systemic therapy for metastatic melanoma

References

• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin.58(2), 71–96 (2008).
   PubMed Web of Science ®Google Scholar
• Luce JK, Thurman WG, Isaacs BL, Talley RW. Clinical trials with the antitumor agent 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide(NSC-45388). Cancer Chemo. Rep.54(2), 119–124 (1970).
   PubMedGoogle Scholar
• Bedikian AY, Millward M, Pehamberger H et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J. Clin. Oncol.24(29), 4738–4745 (2006).
   PubMed Web of Science ®Google Scholar
• Avril MF, Aamdal S, Grob JJ et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a Phase III study. J. Clin. Oncol.22(6), 1118–1125 (2004).
   PubMed Web of Science ®Google Scholar
• Del Prete SA, Maurer LH, O’Donnell J, Forcier RJ, LeMarbre P. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat. Rep.68(11), 1403–1405 (1984).
   PubMedGoogle Scholar
• Rusthoven JJ, Quirt IC, Iscoe NA et al. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J. Clin. Oncol.14, 2083–2090 (1996).
   PubMed Web of Science ®Google Scholar
• Agarwala SS, Ferri W, Gooding W, Kirkwood JM. A Phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma. Cancer85(9), 1979–1984 (1999).
   PubMed Web of Science ®Google Scholar
• Chapman PB, Einhorn LH, Meyers ML et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J. Clin. Oncol.17(9), 2745–2751 (1999).
   PubMed Web of Science ®Google Scholar
• Agarwala SS, Kirkwood JM, Gore M et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a Phase II study. J. Clin. Oncol.22(11), 2101–2107 (2004).
   PubMed Web of Science ®Google Scholar
• Middleton MR, Grob JJ, Aaronson N et al. Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol.18(1), 158–166 (2000).
   PubMed Web of Science ®Google Scholar
• Patel P, Suciu S, Mortier L et al. Exended schedule escalated dose temozolomide vs. dacarbazine in stage IV melanoma: final results of the randomised Phase III study (EORTC 18032). Ann. Oncol.19(Suppl. 8) (2008) (Abstract LB8).
   Google Scholar
• Legha SS, Ring S, Papadopoulos N, Raber M, Benjamin RS. A Phase II trial of taxol in metastatic melanoma. Cancer65(11), 2478–2481 (1990).
   PubMed Web of Science ®Google Scholar
• Einzig AI, Hochster H, Wiernik PH et al. A Phase II study of taxol in patients with malignant melanoma. Invest. New Drugs9(1), 59–64 (1991).
   PubMed Web of Science ®Google Scholar
• Hodi FS, Soiffer RJ, Clark J, Finkelstein DM, Haluska FG. Phase II study of paclitaxel and carboplatin for malignant melanoma. Am. J. Clin. Oncol.25(3), 283–286 (2002).
   PubMed Web of Science ®Google Scholar
• Einzig AI, Schuchter LM, Recio A, Coatsworth S, Rodriquez R, Wiernik PH. Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy. Med. Oncol.13(2), 111–117 (1996).
   PubMed Web of Science ®Google Scholar
• Bedikian AY, Weiss GR, Legha SS et al. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J. Clin. Oncol.13(12), 2895–2899 (1995).
   PubMed Web of Science ®Google Scholar
• Aamdal S, Wolff I, Kaplan S et al. Docetaxel (Taxotere) in advanced malignant melanoma: a Phase II study of the EORTC Early Clinical Trials Group. Eur. J. Cancer30A(8), 1061–1064 (1994).
   PubMedGoogle Scholar
• Ledda F, Bravo AI, Adris S, Bover L, Mordoh J, Podhajcer OL. The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J. Invest. Dermatol.108(2), 210–214 (1997).
   PubMed Web of Science ®Google Scholar
• Ledda MF, Adris S, Bravo AI et al. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat. Med.3(2), 171–176 (1997).
   PubMed Web of Science ®Google Scholar
• Hersh E, O’Day S, Gonzalez R, Ribas A, Samlowski W, Gordon M. Phase II trial of ABI-007 (Abraxane) in previously treated and chemotherapy naive patients with metastatic melanoma. Melanoma Research16, S78 (2006).
   Google Scholar
• Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwarz SL. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J. Exp. Med.161(5), 1169–1188 (1985).
   PubMed Web of Science ®Google Scholar
• Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol.17(7), 2105–2116 (1999).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Yang JC et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl Cancer Inst.85(8), 622–632 (1993).
   PubMed Web of Science ®Google Scholar
• Sparano JA, Fisher RI, Sunderland M et al. Randomized Phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon α-2a in patients with advanced melanoma. J. Clin. Oncol.11(10), 1969–1977 (1993).
   PubMed Web of Science ®Google Scholar
• Petrella T, Quirt I, Verma S, Haynes AE, Charette M, Bak K. Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review. Cancer Treat. Rev.33(5), 484–496 (2007).
   PubMed Web of Science ®Google Scholar
• Schwartzentruber DJ. High-dose interleukin-2 is an intensive treatment regardless of the venue of administration. Cancer J.7(2), 103–104 (2001).
   PubMed Web of Science ®Google Scholar
• Agarwala SS, Glaspy J, O’Day SJ et al. Results from a randomized Phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J. Clin. Oncol.20(1), 125–133 (2002).
   PubMed Web of Science ®Google Scholar
• Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat. Rev.4(5), 336–347 (2004).
   Google Scholar
• Hamid O, Chin K, Li J et al. Dose effect of ipilimumab in patients with advanced melanoma: results from a Phase II, randomized, dose-ranging study. ASCO Meeting Abstracts26(15 Suppl.) (2008) (Abstract 9025).
   Google Scholar
• O’Day SJ, Ibrahim R, DePril V et al. Efficacy and safety of ipilimumab induction and maintenance dosing in patients with advanced melanoma who progressed on one or more prior therapies. ASCO Meeting Abstracts26(15 Suppl.) (2008) (Abstract 9021).
   Google Scholar
• Fischkoff SA, Hersh E, Weber J et al. Durable responses and long-term progression-free survival observed in a Phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma. ASCO Meeting Abstracts23(16 Suppl.) (2005) (Abstract 7525).
   Google Scholar
• Hersh EM, Weber JS, Powderly JD et al. Disease control and long-term survival in chemotherapy-naive patients with advanced melanoma treated with ipilimumab (MDX- 010) with or without dacarbazine. ASCO Meeting Abstracts26(15 Suppl.) (2008) (Abstract 9022).
   Google Scholar
• Maker AV, Phan GQ, Attia P et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a Phase I/II study. Ann. Surg. Oncol.12(12), 1005–1016 (2005).
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Lorigan P, Hersey P et al. A Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. ASCO Meeting Abstracts26(15 Suppl.) (2008) (Abstract 9023).
   Google Scholar
• Tarhini AA, Moschos SS, Schlesselman JJ, Shope-Spotloe J, Demark M, Kirkwood JM. Phase II trial of combination biotherapy of high-dose interferon α-2b and tremelimumab for recurrent inoperable stage III or stage IV melanoma. J. Clin. Oncol. (Meeting Abstracts), 26(15 Suppl.) (2008) (Abstract 9009).
   PubMedGoogle Scholar
• Ribas A, Hauschild A, Kefford R, Gomez-Navarro J, Pavlov D, Marshall MA. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J. Clin. Oncol.26(15 Suppl), LBA9011 (2008).
   Google Scholar
• Attia P, Phan GQ, Maker AV et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol.23(25), 6043–6053 (2005).
   PubMed Web of Science ®Google Scholar
• Ribas A, Camacho LH, Lopez-Berestein G et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J. Clin. Oncol.23(35), 8968–8977 (2005).
   PubMed Web of Science ®Google Scholar
• Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist12(7), 864–872 (2007).
   PubMed Web of Science ®Google Scholar
• Hamid O, Urba WJ, Yellin M et al. Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma. ASCO Meeting Abstracts25(18 Suppl.) (2007) (Abstract 8525).
   Google Scholar
• Wolchok JD, Ibrahim R, DePril V et al. Antitumor response and new lesions in advanced melanoma patients on ipilimumab treatment. ASCO Meeting Abstracts, 26(15 Suppl.) (2008) (Abstract 3020).
   Google Scholar
• Hodi FS, Hoos A, Ibrahim R et al. Novel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an anti-CTLA-4 monoclonal antibody. ASCO Meeting Abstracts26(15 Suppl.) (2008) (Abstract 3008).
   Google Scholar
• Legha SS, Ring S, Eton O et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon α, and interleukin-2 for patients with metastatic melanoma. J. Clin. Oncol.16(5), 1752–1759 (1998).
   PubMed Web of Science ®Google Scholar
• Richards JM, Mehta N, Ramming K, Skosey P. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J. Clin. Oncol.10(8), 1338–1343 (1992).
   PubMed Web of Science ®Google Scholar
• Eton O, Legha SS, Bedikian AY et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a Phase III randomized trial. J. Clin. Oncol.20(8), 2045–2052 (2002).
   PubMed Web of Science ®Google Scholar
• Thompson JA, Gold PJ, Markowitz DR, Byrd DR, Lindgren CG, Fefer A. Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma. Cancer J. Sci. Am.3(Suppl. 1), S29–S34 (1997).
   Google Scholar
• Flaherty LE, Atkins M, Sosman J et al. Outpatient biochemotherapy with interleukin-2 and interferon α-2b in patients with metastatic malignant melanoma: results of two Phase II cytokine working group trials. J. Clin. Oncol.19(13), 3194–3202 (2001).
   PubMed Web of Science ®Google Scholar
• Atkins M, Gollob J. Concurrent Biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2 and IFN-α-2b in patients with metastatic melanoma. Clin. Cancer Res.8(10), 3075–3081 (2002).
   PubMed Web of Science ®Google Scholar
• Atkins MB, Hsu J, Lee S et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon α-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol.26(35), 5748–5754 (2008).
   PubMed Web of Science ®Google Scholar
• Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J. Clin. Oncol.25(34), 5426–5434 (2007).
   PubMed Web of Science ®Google Scholar
• Hamm C, Verma S, Petrella T, Bak K, Charette M. Biochemotherapy for the treatment of metastatic malignant melanoma: a systematic review. Cancer Treat. Rev.34(2), 145–156 (2008).
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Kirkwood JM, Gooding WE, Cai C, Agarwala SS. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J. Clin. Oncol.25(25), 3802–3807 (2007).
   PubMed Web of Science ®Google Scholar
• Salven P, Heikkila P, Joensuu H. Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br. J. Cancer76(7), 930–934 (1997).
   PubMed Web of Science ®Google Scholar
• Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J. Clin. Oncol.19(2), 577–583 (2001).
   PubMed Web of Science ®Google Scholar
• Oku T, Tjuvajev JG, Miyagawa T et al. Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts. Cancer Res.58(18), 4185–4192 (1998).
   PubMed Web of Science ®Google Scholar
• Lev DC, Ruiz M, Mills L, McGary EC, Price JE, Bar-Eli M. Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol. Cancer Ther.2(8), 753–763 (2003).
   PubMed Web of Science ®Google Scholar
• Lev DC, Onn A, Melinkova VO et al. Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J. Clin. Oncol.22(11), 2092–2100 (2004).
   PubMed Web of Science ®Google Scholar
• Munzone E, Testori A, Minchella I et al. A Phase II trial of dacarbazine (DTIC) and bevacizumab in patients with metastatic melanoma. ASCO Meeting Abstracts25(18 Suppl.) (2007) (Abstract 8579).
   Google Scholar
• Perez DG, Suman V, Amatruda T et al. Phase II trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma. ASCO Meeting Abstracts25(18 Suppl.) (2007) (Abstract 8560).
   Google Scholar
• D’Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl Acad. Sci. USA91(9), 4082–4085 (1994).
   PubMed Web of Science ®Google Scholar
• Marriott JB, Clarke IA, Dredge K, Muller G, Stirling D, Dalgleish AG. Thalidomide and its analogues have distinct and opposing effects on TNF-α and TNFR2 during co-stimulation of both CD4+ and CD8+ T cells. Clin. Exp. Immunol.130(1), 75–84 (2002).
   PubMed Web of Science ®Google Scholar
• Eisen T, Boshoff C, Mak I et al. Continuous low dose thalidomide: a Phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br. J. Cancer82(4), 812–817 (2000).
   PubMed Web of Science ®Google Scholar
• Pawlak WZ, Legha SS. Phase II study of thalidomide in patients with metastatic melanoma. Melanoma Res.14(1), 57–62 (2004).
   PubMed Web of Science ®Google Scholar
• Hwu WJ, Krown SE, Menell JH et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J. Clin. Oncol.21(17), 3351–3356 (2003).
   PubMed Web of Science ®Google Scholar
• Clark J, Moon J, Hutchins LF et al. Phase II trial of combination thalidomide (thal) plus temozolomide (TMZ [TT]), in patients with metastatic malignant melanoma (MMM): Southwest Oncology Group S0508. ASCO Meeting Abstracts26(15 Suppl.) (2008) (Abstract 9007).
   Google Scholar
• Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature417(6892), 949–954 (2002).
   PubMed Web of Science ®Google Scholar
• Eisen T, Ahmad T, Flaherty KT et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br. J. Cancer95(5), 581–586 (2006).
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Brose K, Schuchter LM. Sorafenib combined with carboplatin and paclitaxel for metastatic melanoma: progression-free survival and response versus B-RAF status. Ann. Oncol.17(Suppl. 3), iii31–iii33 (2006).
   Google Scholar
• Agarwala SS, Keilholz U, Hogg D et al. Randomized Phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma. ASCO Meeting Abstracts25(18 Suppl.) (2007) (Abstract 8510).
   Google Scholar
• Eisen T, Marais R, Affolter A et al. An open-label Phase II study of sorafenib and dacarbazine as first-line therapy in patients with advanced melanoma. ASCO Meeting Abstracts25(18 Suppl.) (2007) (Abstract 8529).
   Google Scholar
• McDermott DF, Sosman JA, Gonzalez R et al. Double-blind randomized Phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 study group. J. Clin. Oncol.26(13), 2178–2185 (2008).
   PubMed Web of Science ®Google Scholar
• Jansen B, Schlagbauer-Wadl H, Brown BD et al. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat. Med.4(2), 232–234 (1998).
   PubMed Web of Science ®Google Scholar
• Jansen B, Wacheck V, Heere-Ress E et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet356(9243), 1728–1733 (2000).
   PubMed Web of Science ®Google Scholar
• Gehrmann M. Drug evaluation: STA-4783 – enhancing taxane efficacy by induction of Hsp70. Curr. Opin. Investig. Drugs7(6), 574–580 (2006).
   PubMed Web of Science ®Google Scholar
• Berkenblit A, Eder JP Jr, Ryan DP et al. Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors. Clin. Cancer Res.13(2 Pt 1), 584–590 (2007).
   PubMed Web of Science ®Google Scholar
• O’Day S, Gonzalez R, Lawson D et al. Subgroup analysis of efficacy and safety analysis of a randomized, double-blinded controlled Phase II study of STA-4783 in combination with paclitaxel in patients with metastatic melanoma. ASCO Meeting Abstracts25(18 Suppl.) (2007) (Abstract 8528).
   Google Scholar
• Lawson DH, Gonzalez R, Weber RW et al. 2-year overall survival (OS) results of a Phase II trial of elesclomol (formerly STA-4783) and paclitaxel in stage IV metastatic melanoma (MM). ASCO Meeting Abstracts26(15 Suppl.) (2008) (Abstract 20023).
   Google Scholar
• Korn EL, Liu P-Y, Lee SJ et al. Meta-analysis of Phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future Phase II trials. J. Clin. Oncol.26(4), 527–534 (2008).
   PubMed Web of Science ®Google Scholar